Not applicableUnknownNCT03958188What this trial is testingPreOPerative Imaging of NeuroEndocrine TumorsWho this might be right forNeuro-endocrine TumorsSmall Intestine Cancer Hospices Civils de Lyon 47
Not applicableUnknownNCT03812939What this trial is testingRecurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin AnalogsWho this might be right forGastric NET Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Study completedNCT02955069What this trial is testingStudy of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)Who this might be right forWell-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT00510068What this trial is testingEfficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsWho this might be right forAdvanced Neuroendocrine Tumors of Pancreatic Origin Novartis Pharmaceuticals 410
Early research (Phase 1)Ended earlyNCT04258592What this trial is testing18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine TumorsWho this might be right forNeural Crest TumorNeuroendocrine Tumors Universitaire Ziekenhuizen KU Leuven 6
Not applicableUnknownNCT03982264What this trial is testingEndoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mmWho this might be right forRectal Neuroendocrine Tumor Nanfang Hospital, Southern Medical University 90
Not applicableStudy completedNCT03791346What this trial is testingPancreatectomy for NET: External Evaluation of WHO 2017 Grading SystemWho this might be right forPancreatic Surgery University Hospital, Montpellier 138
Testing effectiveness (Phase 2)WithdrawnNCT06233903What this trial is testing18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous SystemWho this might be right forNeuroblastomaPheochromocytomaParaganglioma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Not applicableLooking for participantsNCT07319416What this trial is testingDCEUS to Assess Treatment Response to PRRT in GEP-NETWho this might be right forNETRadionucleide TherapyContrast Enhanced Ultrasound Fondazione Policlinico Universitario Agostino Gemelli IRCCS 30
Testing effectiveness (Phase 2)WithdrawnNCT04276597What this trial is testingPhase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.Who this might be right forPulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more Excel Diagnostics and Nuclear Oncology Center
Testing effectiveness (Phase 2)Study completedNCT04296149What this trial is testingBeta- Probe and Surgery in GEP NET: Evaluation of a New ProbeWho this might be right forNeuroendocrine Tumors European Institute of Oncology 5
Testing effectiveness (Phase 2)Ended earlyNCT02736448What this trial is testing177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsWho this might be right forGastro-entero-pancreatic Neuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)Study completedNCT03352934What this trial is testingAvelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After ChemotherapyWho this might be right forCancer Johannes Gutenberg University Mainz 60
Testing effectiveness (Phase 2)UnknownNCT05709171What this trial is testingDual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine NeoplasmsWho this might be right forGEP-NETNeuroendocrine TumorsNeuroendocrine Carcinoma+1 more Rigshospitalet, Denmark 200
Early research (Phase 1)Ended earlyNCT05364944What this trial is testingAssess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)Who this might be right forAcromegalyGEP-NET Debiopharm International SA 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT06790706What this trial is testingIMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersWho this might be right forPeritoneal MesotheliomaGestational Trophoblastic TumorAnaplastic Thyroid Carcinomas+3 more Hospices Civils de Lyon 27
Not applicableStudy completedNCT04207762What this trial is testing18F-AmBF3-TATE PET/CT for Imaging NET PatientsWho this might be right forNeuroendocrine Tumors British Columbia Cancer Agency 10
Not applicableStudy completedNCT06853457What this trial is testingA Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver MetastasesWho this might be right forNeuroendocrine Tumors, NET First Affiliated Hospital, Sun Yat-Sen University 257
Not applicableUnknownNCT06402695What this trial is testingObservational Study on GEP-and Pulm-NET Treated at FPGWho this might be right forNeuroendocrine TumorsGep NetPulmonary Neuroendocrine Neoplasm Fondazione Policlinico Universitario Agostino Gemelli IRCCS 650
Not applicableUnknownNCT04444401What this trial is testingRegistry on NEN Patients and COVID-19Who this might be right forNeuroendocrine TumorsCOVID-19 European Institute of Oncology 50